Co-expression of CD44v6 and MMP2 Predicts Lung Metastasis and Unfavorable Prognosis in Osteosarcoma

Overview

Journal Future Oncol

Specialty Oncology

Date 2024 Jul 16

PMID 39011948

Authors

Shoulei Liang

Liang Li

Zhiliang Guo

Haijing Sun

Yan Yang

Affiliations

Soon will be listed here.

Abstract

To evaluate the prognostic significance of CD44 variant v6 (CD44v6) and matrix metalloproteinases 2 (MMP2) expression in patients with surgically resected osteosarcoma. CD44v6 and MMP2 expression were immunohistochemically detected in 113 primary osteosarcoma patients at our institute between 2001 and 2019. Both CD44v6 and MMP2 were independent predictors for metastasis-free and overall survival. An extended predictive range and improved sensitivity were observed when the combined effects of CD44v6 and MMP2 were considered. Specifically, patients with CD44v6+ and MMP2+ expression were more susceptible to lung metastasis and exhibited the poorest survival rates compared with the other groups. The combination of CD44v6 and MMP2 may serve as a precise prognostic indicator for predicting metastatic progression and survival outcomes in patients with osteosarcoma.

Citing Articles

Invasion and metastasis in cancer: molecular insights and therapeutic targets.

Li Y, Liu F, Cai Q, Deng L, OuYang Q, Zhang X Signal Transduct Target Ther. 2025; 10(1):57.

PMID: 39979279 PMC: 11842613. DOI: 10.1038/s41392-025-02148-4.

References

Liao C, Lai K, Huang A, Yang J, Lin J, Wu S . Gallic acid inhibits migration and invasion in human osteosarcoma U-2 OS cells through suppressing the matrix metalloproteinase-2/-9, protein kinase B (PKB) and PKC signaling pathways. Food Chem Toxicol. 2012; 50(5):1734-40. DOI: 10.1016/j.fct.2012.02.033. View

Ritter J, Bielack S . Osteosarcoma. Ann Oncol. 2010; 21 Suppl 7:vii320-5. DOI: 10.1093/annonc/mdq276. View

Maugg D, Rothenaigner I, Schorpp K, Potukuchi H, Korsching E, Baumhoer D . New small molecules targeting apoptosis and cell viability in osteosarcoma. PLoS One. 2015; 10(6):e0129058. PMC: 4454490. DOI: 10.1371/journal.pone.0129058. View

Chen C, Zhao S, Karnad A, Freeman J . The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018; 11(1):64. PMC: 5946470. DOI: 10.1186/s13045-018-0605-5. View

Ni J, Cozzi P, Hao J, Beretov J, Chang L, Duan W . CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance. Prostate. 2014; 74(6):602-17. DOI: 10.1002/pros.22775. View

Liu D, Kang H, Gao M, Jin L, Zhang F, Chen D . Exosome-transmitted circ_MMP2 promotes hepatocellular carcinoma metastasis by upregulating MMP2. Mol Oncol. 2020; 14(6):1365-1380. PMC: 7266270. DOI: 10.1002/1878-0261.12637. View

Kuryu M, Ozaki T, Nishida K, Shibahara M, Kawai A, Inoue H . Expression of CD44 variants in osteosarcoma. J Cancer Res Clin Oncol. 1999; 125(11):646-52. DOI: 10.1007/s004320050329. View

Wang Z, Zhao K, Hackert T, Zoller M . CD44/CD44v6 a Reliable Companion in Cancer-Initiating Cell Maintenance and Tumor Progression. Front Cell Dev Biol. 2018; 6:97. PMC: 6122270. DOI: 10.3389/fcell.2018.00097. View

Biermann J, Chow W, Reed D, Lucas D, Adkins D, Agulnik M . NCCN Guidelines Insights: Bone Cancer, Version 2.2017. J Natl Compr Canc Netw. 2017; 15(2):155-167. DOI: 10.6004/jnccn.2017.0017. View

10.

Ji H, Kong L, Wang Y, Hou Z, Kong W, Qi J . CD44 expression is correlated with osteosarcoma cell progression and immune infiltration and affects the Wnt/β-catenin signaling pathway. J Bone Oncol. 2023; 41:100487. PMC: 10242553. DOI: 10.1016/j.jbo.2023.100487. View

11.

Wang L, Duan W, Kang L, Mao J, Yu X, Fan S . Smoothened activates breast cancer stem-like cell and promotes tumorigenesis and metastasis of breast cancer. Biomed Pharmacother. 2014; 68(8):1099-104. DOI: 10.1016/j.biopha.2014.09.012. View

12.

Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M . CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 2014; 14(3):342-56. DOI: 10.1016/j.stem.2014.01.009. View

13.

Cho H, Lee T, Park J, Park K, Choe J, Sin D . Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. J Biochem Mol Biol. 2007; 40(6):1069-76. DOI: 10.5483/bmbrep.2007.40.6.1069. View

14.

Xie Z, Gao Y, Ho C, Li L, Jin C, Wang X . Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment. Gut. 2021; 71(3):568-579. DOI: 10.1136/gutjnl-2020-323014. View

15.

Zhang M, Zhang X . Association of MMP-2 expression and prognosis in osteosarcoma patients. Int J Clin Exp Pathol. 2016; 8(11):14965-70. PMC: 4713615. View

16.

Regan D, Chow L, Das S, Haines L, Palmer E, Kurihara J . Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma. Clin Cancer Res. 2021; 28(4):662-676. PMC: 8866227. DOI: 10.1158/1078-0432.CCR-21-2105. View

17.

Egeblad M, Werb Z . New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2(3):161-74. DOI: 10.1038/nrc745. View

18.

Meyers P, Heller G, Healey J, Huvos A, Lane J, Marcove R . Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992; 10(1):5-15. DOI: 10.1200/JCO.1992.10.1.5. View

19.

Bauvois B . New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta. 2011; 1825(1):29-36. DOI: 10.1016/j.bbcan.2011.10.001. View

20.

Hosseini A, Eghtedari A, Mirzaei A, Babaheidarian P, Nekoufar S, Khademian N . The clinical significance of CD44v6 in malignant and benign primary bone tumors. BMC Musculoskelet Disord. 2023; 24(1):607. PMC: 10367246. DOI: 10.1186/s12891-023-06738-7. View